Recent evidence has resurrected the concept of specialized populations of T lymphocytes that are able to suppress an antigenspecific immune response. T-regulatory cells (T-reg) have been characterized as CD4 þ CD25 þ T cells. Previous reports describing differential gene expression analysis have shown that the glucocorticoid-induced tumor necrosis family receptor family-related gene (GITR) is upregulated in these cells. Furthermore, antibodies specific for GITR have been shown to inhibit the T-suppressor function of CD4 þ CD25 þ T-reg. The ligands for both mouse and human GITR have been cloned recently. We have inserted the sequences for natural, membrane-bound GITR-ligand (GITR-L) and a truncated secreted form of GITR-L (GITR-Lsol) into the adenovirus-5 genome. Coculture experiments show that cells infected with Ad-GITR-L and supernatants from cells infected with Ad-GITR-Lsol can increase the proliferation of both CD4 þ CD25-and CD8 þ T cells in response to anti-CD3 stimulation, in the presence, as well as in the absence, of CD4 þ CD25 þ T cells. The virus constructs were injected into growing B16 melanoma tumors. Ad-GITR-L was shown to attract infiltration with both CD4 þ and CD8 þ T cells. Both constructs were shown to inhibit tumor growth.
M
anipulation of the immune response depends upon the knowledge of the numerous intercellular signal systems required for the coordinated activation and regulation of the immune response. This could be for its activation, as for the immunotherapy of cancer, or for its inhibition, as for the treatment of autoimmune disease. In some disease situations, immune regulatory systems are diverted towards the disease's advantage. In cancer, it has been well established that patients with cancer, especially late stage disease, are in a state of immune anergy. 1 This is often associated with T-lymphocyte-mediated immune suppressor cells.
2 Suppressor T-cell activity was originally described in the 1970s and was associated with CD8 þ T cells. 3 T-cell-mediated immune suppression was also associated with a variety of soluble suppressor 4 and contrasuppressor factors. 5 With the advent of T-cell cloning and recombinant DNA technologies, these activities remained elusive and were eventually lost from mainstream immunology. More recently, however, new methods of T-cell culture and differential gene expression array technologies have enabled the identification of T-cell populations with immune suppressive activity.
One such immunosuppressive T-cell population, T-regulatory cells (T-reg), which express both CD4 and CD25, has been shown to be unresponsive to proliferation induction by TCR crosslinking with anti-CD3 antibodies. Moreover, this T-cell population is able to inhibit the anti-CD3-meditated proliferation by CD25À T lymphocytes. The immunosuppressive role of CD4 þ CD25 þ T cells has been implicated in protecting tumors from immune attack and aiding in their growth in mouse models. 6 Increased numbers of CD4 þ CD25 þ cells have been observed in the circulation of patients with advanced cancers 2 and it is postulated that they are involved in aiding the growth of human tumors as well. Treatment of tumor-bearing mice with CD4 þ CD25 þ T-cell depleted lymph node lymphocytes has been shown to retard tumor growth. 6 In addition, the decrease in immunosuppressive activity by CD4 þ CD25 þ T cells by treatment of tumorbearing rats with low-dose cyclophosphamide resulting in more effective immunotherapy with a tumor vaccination strategy has been described recently.
Comparative gene expression array analysis has shown that the genes for a limited number of cell surface markers are differentially expressed by CD4 þ CD25 þ T cells. 8 Flow cytometry analysis of cell surface expression of several of these markers indicated that they were upregulated at the protein level, on both resting and activated CD4 þ CD25 þ T cells. These include GITR, OX40, 4-1BB, Ly6, CD103 and CTLA-4. 8 Functional testing with specific antibodies showed that only anti-GITR antibody could inhibit immune suppressive activity of these cells. 8 In vivo testing has shown that antibodies to GITR can induce organ-specific autoimmunity. 9 More recently, it has been shown that even in the absence of CD25 þ CD4 þ T-reg cells, anti-GITR can increase the proliferative response of both CD4 þ and CD8 þ T cells to TCR crosslinking with anti-CD3. 10 This suggests that GITR not only provides a negative signal to T-regs, which inhibits their suppressive activity; but it may also be costimulatory for CD25-T cells, both CD4 þ and CD8 þ . In addition, GITR activation is associated with the inhibition of T-cell apoptosis from activation induced cell death (AICD).
11
The ligands for both human and mouse GITR have been cloned. CHO cells stably transfected with murine GITR-L were shown to have the same costimulatory effect on CD25-T cells of both CD4 þ or CD8 þ phenotype. 10 This was shown to be dependent upon the expression of GITR by T cells. 10 More recently, it has been shown that a soluble form of mouse GITR-L can block in vitro suppression mediated by CD4 þ CD25 þ T-reg cells. 12 We have cloned murine GITR-L into an adenovirus-5 vector, in both membrane anchored and secreted forms and asked whether tumor cells infected with this construct can activate T cells in the presence of CD4 þ CD25 þ suppressive T-reg cells. In addition, we have injected the constructs into growing B16 tumors to determine whether Ad-GITR-L has any therapeutic effect on tumor growth. B16 is a very aggressive melanoma cell line known to be associated with immune suppression. 13 
Materials and methods

Cloning and construction of membrane bound and soluble GITR-L
Splenocytes from C57BL/6 mice were used to extract mRNA with RNA Now (Ozyme). Murine GITR-L cDNA, complete sequence and extracellular domains, were amplified by RT-PCR (Platinum Quantitative RT-PCR, ThermoscriptTM one-step system, Invitrogen) with specific oligonucleotides based on the sequence data available in NCBI data bank (access number AY359852). A 546-bp product encoding the natural form of GITR-L was cloned in an adenoviral shuttle plasmid as previously described. 14 The extracellular domain of GITR-L (nucleotides 127-519) was cloned in frame between the sequence encoding for the signal peptide of the light chain of 2F5 antibody and two tag sequences, myc tag and PolyHis, in view of potential purification possibilities. The resulting gene was cloned in an adenoviral shuttle plasmid as previously described. 14 
Adenovirus production and titration
The sequence encoding each protein was inserted in an adenoviral shuttle plasmid containing a CMV-driven expression cassette surrounded by adenoviral sequences (adenoviral nucleotides 1-458 and nucleotides 3328-5788, respectively) to allow generation of the vector genome by homologous recombination. 15 The resulting adenoviral vectors are E3 (nucleotides 28592-30470) and E1 (nucleotides 459-3327) deleted, with the E1 region replaced by the expression cassette containing, from 5 0 to 3 0 , the CMV immediate-early enhancer/promoter, a chimeric human b-globin/IgG intron, the sequence encoding either of the two GITR-L forms and the SV40 late polyadenylation signal. The recombinant adenoviruses were generated by transfecting the PacI linearized viral genomes into the PER-C6 complementation cell line. 16 Virus propagation, purification and titration were performed as described previously. 14 
Cell culture
Murine melanoma cells B16-F0 (ATCC, CRL-6322) were grown at 371C in DMEM (Gibco) supplemented with 10% fetal calf serum (FCS) and antibiotics. All cell lines were tested negative for mycoplasma using Hoechst dye, cell culture and PCR. B16-F0 were previously transfected with the Coxsackie adenovirus receptor (B16-F0 CAR) in order to facilitate infection of the murine B16-F0 cells by the human adenovirus construct (kindly provided by P Erbs manuscript in preparation).
Antibodies and cytokines
Rabbit polyclonal antibody to mouse GITR-L was purchased from Alexis s Biochemicals (UK). Anti-mouse CD8, anti-mouse CD4 and anti-mouse CD3 (145-2C11) were purchased from BD Pharmingen (San Diego, CA).
Detection of GITR-L expression
B16-F0 CAR cells were infected in suspension with adenoviral vectors as previously described at multiplicity of infection (MOI) of 10 (30 min incubation of cells with virus dilutions in 100 ml of PBS supplemented with 2% FCS, 1% cations).
14 Cells were then cultured in complete medium containing 2% FCS for 24 h. Membrane-bound GITR-L expression was then analyzed by flow cytometry using a FACScant flow cytometer and CELLquestt software (Becton Dickinson, Mountain View, CA) with rabbit polyclonal antibody to mouse GITR-L.
Membrane-bound GITR-L and GITR-Lsol protein expression were analyzed by Western blot according to the ECLt Western blotting protocol provided by Amersham Life Sciences (Buckinghamshire, UK). B16-F0 CAR cells were infected at an MOI of 50. At 48 hours after infection, supernatants were collected and assessed by Western blot on 4-12% Nupage gel (Novex, Invitrogen, Cergy Pontoise, France) using polyclonal rabbit antibody to mouse GITR-L and the ECL detection system (Amersham Life Sciences).
Proliferation assays
The T-cell proliferation assay used was essentially as described elsewhere. 8 Briefly CD4 þ CD25 þ T cells, CD4 þ CD25-T cells or CD8 þ T cells were purified from spleen cell suspensions prepared from 7-week-old C57Bl6 mice using CD4 þ CD25 þ regulatory T-cell Isolation Kit and CD8a þ T-cell Isolation Kit purchased from Miltenyl Biotec (Bergisch Gladbach, Germany). 
In vivo experiments
The mouse B16-F0 CAR tumors were established by injecting 100 ml of PBS containing 3 Â 10 5 cells subcutaneously into the flanks of 6-week-old female immunocompetent C57Bl6 mice (IFFA CREDO, Lyon, France). When tumors were palpable, the mice were randomized (10 per group) and their tumors were injected, as indicated, with indicated adenovirus vectors as follows. Viruses were resuspended in 10 mM Tris-HCl, pH 7.5, 10 mM MgCl 2 at a concentration of 5 Â 10 8 IU/100 ml, and injected into the tumors. Tumor sizes were measured using calipers. Tumor volumes were calculated in cubic millimeter using the formula: (p/6)(length Â width Â height).
Statistical analyses
Statistical analyses were performed using the log-rank application for Kaplan-Meir survival curves (Statistica 5.1 software; StatSoft). A Po.05 was considered statistically significant.
Immunohistochemistry of in vivo response
Tumors were established and injected with the various viruses as described above for in vivo experiments. Five Figure 1 Schematic representation of the recombinant adenoviral vectors encoding GITR-L and GITR-Lsol genes. All indicated adenovirus vectors are derived from human adenovirus type 5 deleted in the E1 region (nucleotides 459-3327) and in the E3 region (nucleotides 28592-30470). The E1 region was replaced by an expression cassette containing the different transgenes. CMVpro, CMV promoter; ivs, chimeric human b-globin/IgG intron; sp, signal peptide from 2F5 antibody; tag, myc tag and PolyHis; pA, SV40 late polyadenylation signal. Bypassing tumor-associated immune suppression B Calmels et al days after the last adenovirus injection, tumors were excised and fixed in 10% neutral formalin. The samples were embedded and sectioned to 5 mm. After rinsing and fixing with acetone, slides were incubated with primary antibodies. After washing, slides were incubated with the secondary rabbit anti-rat immunoglobulin. Slides were then rinsed and incubated with peroxidase-conjugated goat anti-rabbit Ab for amplification of the response, followed by DAB (diamino-benzidine) color development. Slides were observed at Â 20 magnification.
Results and discussion
Murine GITR-L was cloned by PCR from murine spleen cells as described in the Materials and methods. This DNA was sequenced and cloned into adenovirus-5 as described and as shown in Figure 1 . A second construct encoding the extracellular portion only of GITR-L was produced by PCR (Fig 1) and is referred to as GITR-Lsol. Expression of GITR-L protein by Ad-GITR-L and Ad-GITR-Lsol was confirmed by Western blot (Fig 2a) . Bypassing tumor-associated immune suppression B Calmels et al B16-F0-CAR melanoma cells were infected with the two viral constructs and the cell pellets and cell supernatants were probed with the rabbit anti-GITR-L antibody as described in Materials and methods (Fig 2a) . As expected, the native form of GITR-L is associated with the cell pellet while very little is found in the culture supernatant. In contrast, most GITR-Lsol is found in the cell culture supernatant. The GITR-Lsol protein is slightly larger than native GITR-L due to the addition of the signal peptide and tag sequences as shown in Figure 1 . Expression of cell surface GITR-L protein was confirmed by FACS analysis of B16 tumor cells infected with the Ad-GITR-L construct, as shown in Figure 2b . The effect of GITR-L on T-cell proliferation, in the presence of immunosuppressive CD4 þ CD25 þ , was tested in vitro as described. B16-F0-CAR cells were infected with Ad-GITR-L and inactivated with mitomycin-C. The effect of these cells on the anti-CD3-induced proliferation of T cells, in the presence or absence of T-reg cells, was then assessed. In this system, it is clear that CD4 þ CD25-T cells (Fig 3a) and CD8 þ T cells (Fig 3b) proliferate to a modest extent in the presence of anti-CD3 but in the absence of T-reg (CD4 þ CD25 þ ) cells. The addition of an excess of enriched T-reg cells eliminates the proliferative capacity of CD4 þ CD25- (Fig 3a) and CD8 þ (Fig 3b) T cells. The addition of mitomycin-C-treated B16-F0-CAR cells or mitomycin-C-treated, Ad-null infected B16-F0-CAR cells does little to the proliferation of CD4 þ CD25- (Fig 3a) or CD8 þ (Fig 3b) T cells in either the presence or absence of T-reg cells. In contrast, the addition of the same number of Ad-GITR-L-infected, mitomycin-C-treated B16 cells greatly enhances the proliferative capacity of both CD4 þ CD25- (Fig 3a) and CD8 þ (Fig 3b) T cells. This enhanced proliferation is observed in both the presence and absence of excess CD4 þ CD25 þ T-reg cells. From these data it cannot be distinguished whether the proliferationenhancing effect of GITR-L is due to inactivation of the immunosuppression exerted by T-reg cells or due to a costimulatory effect of GITR-L directly on CD25-T cells. Both activities of GITR-L have been described in the literature. 9, 11 An adenovirus expressing a secreted form of GITR-L was also produced, as shown in Figures 1 and 3 . Supernatants of B16 cells infected with this virus were titrated for costimulatory activity on CD4 þ CD25-and CD8 þ CD25-T cells in the presence of T-reg cells. The results are shown in Figure 4 . In this experiment, there is a slight effect on the stimulation of the T-reg cells themselves. There was a more pronounced enhancement of CD4 þ CD25-stimulation by GITR-Lsol-containing supernatant, in the presence of T-reg cells and anti-CD3. The costimulatory effect titred out at a dilution of 1/10. Interestingly, the effect on CD8 þ T cells was much less (Fig 4) than that observed with native GITR-L. In the absence of T-reg cells there was a very slight enhancement of CD8 þ T-cell stimulation, about two-fold, but at very low cpm values (data not shown). It is known that most murine CD8 þ cells require ''help'' in the form of cytokines or CD4 þ cells to proliferate in response to antigenic stimulus. 17 Thus, it is consistent that T cells proliferate poorly in response to anti-CD3 in the experiment described in Figure 3 . This may also be involved in the lack of CD8 þ proliferation in response to anti-CD3 þ GITR-Lsol in the presence of T-reg cells. Alternatively, since only low-level proliferation was induced, as evidenced by the low 3 H-TdR incorporation, the amount of GITR-Lsol in the culture supernatant may be too low to see a pronounced effect.
We next tested the in vivo effects of Ad-GITR-L. C57/ Bl6 mice were injected with B16-F0-CAR cells as Figure 4 In vitro T-cell proliferation. CD4 þ CD25 þ alone or mixed with CD4 þ CD25-or CD8 þ were stimulated for 3 days with anti-CD3 in the presence of serial dilutions of GITR-Lsol containing supernatants from B16-F0-CAR cells infected with Ad-GITR-Lsol.
Bypassing tumor-associated immune suppression B Calmels et al described. When tumors were palpable, mice were either left uninjected or their tumors were injected with Ad-GITR-L. Five days later, mice were killed and their tumors excised and stained for T-cell infiltration. A typical infiltration pattern is shown in Figure 5a . Pronounced infiltration by both CD4 þ and CD8 þ T cells in response to Ad-GITR-L was observed. Expression of GITR-L was also clearly demonstrable (Fig 5b) . The effect of both adenovirus constructs on tumor growth was also assessed. We have used the aggressive B16 melanoma tumor model to test the effects of GITRL on immune regulation. B16 melanoma is known to be a difficult model, associated with immune suppression and resistant to many immunotherapy interventions. 6, 13 In the experiment described in Figure 6a and b, B16-F0-CAR tumor cells were injected subcutaneously into C57/Bl6 mice as described. After 15 days, when tumors were palpable, they were injected with the control adenovirus Ad-GITR-L or Ad-GITR-Lsol. The tumor growth curves (Fig 6a) show clearly the tumor growth inhibiting capabilities of both Ad-GITR-L and Ad-GITR-Lsol. This translates into an impact on survival, with 45% survival at 50 days in the group of mice injected with Ad-GITR-Lsol (Fig 6b) . No overt signs of autoimmunity (vitiligo or weight loss) were observed in the mice who had rejected their tumors. Bypassing tumor-associated immune suppression B Calmels et al It has been reported elsewhere 9 that monomeric Fab fragments of anti-GITR antibody are unable to neutralize immunosuppression by CD4 þ CD25 þ T-reg cells, whereas the dimeric, complete antibody was able to. In the in vivo experiment described in Figure 6 , the construct Ad-GITR-Lsol produces monomeric, soluble GITR-L and appears to inhibit tumor growth more effectively than the construct expressing cell-bound GITR-L which would be more likely to crosslink GITR on the cell surface of T-reg cells. The observation that Ad-GITRLsol is more effective at inhibiting tumor growth in vivo is also in contrast with the in vitro data where the effect of Ad-GITR-L infected cells was more striking than that of supernatant from Ad-GITR-Lsol infected B16 cells, especially on CD8 þ T cells. The demonstration that the costimulatory effect of supernatant from Ad-GITR-Lsol-infected cells titrates out so readily suggests that higher concentrations would be more effective. Much higher local concentrations of GITR-Lsol would likely be produced in vivo, enabling GITR-Lsol to be more active. Also, it cannot be excluded that GITR-Lsol may act systemically as well, whereas native GITR-L expression would be restricted to the tumor and draining lymph nodes. The biological mechanisms of the in vivo Bypassing tumor-associated immune suppression B Calmels et al activities of GITR-L and GITR-Lsol remain to be elucidated. Strategies to break the inhibition of immune impairment mediated, at least in part, by cellular immune regulatory mechanisms, are now being applied clinically in antigen-specific cancer immunotherapy studies. Efforts to eliminate immune suppressor cells by prevaccination treatment with low-dose cyclophosphamide have been made over the past 20 years [18] [19] [20] with some notable immune-enhancing effects. More recently, immune enhancement by the vaccination of melanoma patients, together with anti-CTLA-4 antibody, 21 has been shown. Clinical responses together with significant autoimmunity were observed. 21 The combined effects of GITR-L on the inhibition of T-reg-mediated immune suppression, direct costimulation of effector T cells and protection of effector T cells from AICD make the combination of GITR-L with cancer immunotherapy an attractive additional strategy. Treatment with GITR-L whether by gene transfer or by systemic injection of recombinant GITRLsol protein could translate into significant clinical benefit in the setting of cancer immunotherapy.
